• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

万古霉素-乳链菌肽(1-12)杂合体恢复了对万古霉素耐药肠球菌的活性。

The vancomycin-nisin(1-12) hybrid restores activity against vancomycin resistant Enterococci.

作者信息

Arnusch Christopher J, Bonvin Alexandre M J J, Verel Anne Marie, Jansen Wouter T M, Liskamp Rob M J, de Kruijff Ben, Pieters Roland J, Breukink Eefjan

机构信息

Department of Chemical Biology and Organic Chemistry, Institute of Biomembranes, Utrecht University, Padualaan 8, 3584 CH Utrecht, The Netherlands.

出版信息

Biochemistry. 2008 Dec 2;47(48):12661-3. doi: 10.1021/bi801597b.

DOI:10.1021/bi801597b
PMID:18989934
Abstract

Lipid II is a crucial component in bacterial cell wall synthesis [Breukink, E., et al. (1999) Science 286, 2361-2364]. It is the target of a number of important antibiotics, which include vancomycin and nisin [Breukink, E., and de Kruijff, B. (2006) Nat. Rev. Drug Discovery 5, 321-332]. Here we show that a hybrid antibiotic that consists of vancomycin and nisin fragments is significantly more active than the separate fragments against vancomycin resistant entercocci (VRE). Three different hybrids were synthesized using click chemistry and compared. Optimal spacer lengths and connection points were predicted using computer modeling.

摘要

脂 II 是细菌细胞壁合成中的关键成分[Breukink, E., 等人 (1999) 《科学》286, 2361 - 2364]。它是多种重要抗生素的作用靶点,其中包括万古霉素和乳链菌肽[Breukink, E., 和 de Kruijff, B. (2006) 《自然综述:药物发现》5, 321 - 332]。在此我们表明,一种由万古霉素和乳链菌肽片段组成的杂合抗生素,相较于单独的片段,对耐万古霉素肠球菌(VRE)的活性显著更高。使用点击化学合成了三种不同的杂合体并进行比较。利用计算机建模预测了最佳间隔长度和连接点。

相似文献

1
The vancomycin-nisin(1-12) hybrid restores activity against vancomycin resistant Enterococci.万古霉素-乳链菌肽(1-12)杂合体恢复了对万古霉素耐药肠球菌的活性。
Biochemistry. 2008 Dec 2;47(48):12661-3. doi: 10.1021/bi801597b.
2
Importance of the structure of vancomycin binding pocket in designing compounds active against vancomycin-resistant enterococci (VRE).万古霉素结合口袋结构在设计抗万古霉素耐药肠球菌(VRE)活性化合物中的重要性。
J Antibiot (Tokyo). 2006 Sep;59(9):543-52. doi: 10.1038/ja.2006.75.
3
Resistance of Gram-positive bacteria to nisin is not determined by lipid II levels.革兰氏阳性菌对乳链菌肽的抗性并非由脂磷壁酸质水平决定。
FEMS Microbiol Lett. 2004 Oct 1;239(1):157-61. doi: 10.1016/j.femsle.2004.08.033.
4
Lipid II: a central component in bacterial cell wall synthesis and a target for antibiotics.脂 II:细菌细胞壁合成的核心成分及抗生素作用靶点。
Prostaglandins Leukot Essent Fatty Acids. 2008 Sep-Nov;79(3-5):117-21. doi: 10.1016/j.plefa.2008.09.020. Epub 2008 Nov 12.
5
Differential inhibition of Staphylococcus aureus PBP2 by glycopeptide antibiotics.糖肽类抗生素对金黄色葡萄球菌青霉素结合蛋白2的差异性抑制作用
J Am Chem Soc. 2005 Mar 16;127(10):3250-1. doi: 10.1021/ja043849e.
6
Targeting extracellular pyrophosphates underpins the high selectivity of nisin.靶向细胞外焦磷酸盐是乳链菌肽具有高选择性的基础。
FASEB J. 2004 Dec;18(15):1862-9. doi: 10.1096/fj.04-2358com.
7
Expanding role of lipid II as a target for lantibiotics.脂磷壁酸质II作为羊毛硫抗生素作用靶点的作用扩展
Future Microbiol. 2007 Oct;2(5):513-25. doi: 10.2217/17460913.2.5.513.
8
Getting closer to the real bacterial cell wall target: biomolecular interactions of water-soluble lipid II with glycopeptide antibiotics.更接近真实的细菌细胞壁靶点:水溶性脂 II 与糖肽类抗生素的生物分子相互作用
Chemistry. 2003 Apr 4;9(7):1556-65. doi: 10.1002/chem.200390179.
9
Multivalent antibiotics via metal complexes: potent divalent vancomycins against vancomycin-resistant enterococci.通过金属配合物的多价抗生素:针对耐万古霉素肠球菌的强效二价万古霉素
J Med Chem. 2003 Nov 6;46(23):4904-9. doi: 10.1021/jm030417q.
10
Selective cleavage of D-Ala-D-Lac by small molecules: re-sensitizing resistant bacteria to vancomycin.小分子对D-丙氨酰-D-乳酸的选择性切割:使耐药细菌对万古霉素重新敏感
Science. 2001 Aug 24;293(5534):1484-7. doi: 10.1126/science.1060324.

引用本文的文献

1
Leveraging strain competition to address antimicrobial resistance with microbiota therapies.利用菌株竞争通过微生物群疗法解决抗生素耐药性问题。
Gut Microbes. 2025 Dec;17(1):2488046. doi: 10.1080/19490976.2025.2488046. Epub 2025 Apr 7.
2
Vancomycin-Teixobactin Conjugates.万古霉素-替考拉宁结合物
J Am Chem Soc. 2025 Feb 26;147(8):6343-6348. doi: 10.1021/jacs.4c17175. Epub 2025 Feb 14.
3
Unexpected vulnerability of to polymyxin B under anaerobic condition.在厌氧条件下对多粘菌素B的意外易感性。
Gut Microbes. 2024 Jan-Dec;16(1):2438465. doi: 10.1080/19490976.2024.2438465. Epub 2024 Dec 11.
4
Engineering of Nisin as a Means for Improvement of Its Pharmacological Properties: A Review.乳链菌肽工程化:改善其药理特性的手段综述
Pharmaceuticals (Basel). 2023 Jul 26;16(8):1058. doi: 10.3390/ph16081058.
5
Synthesis of vancomycin fluorescent probes that retain antimicrobial activity, identify Gram-positive bacteria, and detect Gram-negative outer membrane damage.合成万古霉素荧光探针,保留抗菌活性,识别革兰氏阳性菌,并检测革兰氏阴性菌外膜损伤。
Commun Biol. 2023 Apr 14;6(1):409. doi: 10.1038/s42003-023-04745-x.
6
Recent Advances in the Development of Semisynthetic Glycopeptide Antibiotics: 2014-2022.近年来半合成糖肽类抗生素的研究进展:2014-2022 年。
ACS Infect Dis. 2022 Aug 12;8(8):1381-1407. doi: 10.1021/acsinfecdis.2c00253. Epub 2022 Jul 27.
7
Nisin Variants Generated by Protein Engineering and Their Properties.通过蛋白质工程产生的乳酸链球菌素变体及其特性。
Bioengineering (Basel). 2022 Jun 10;9(6):251. doi: 10.3390/bioengineering9060251.
8
Vancomyxins: Vancomycin-Polymyxin Nonapeptide Conjugates That Retain Anti-Gram-Positive Activity with Enhanced Potency against Gram-Negative Strains.万古霉素-多粘菌素九肽缀合物:保持抗革兰氏阳性活性的万古霉素-多粘菌素九肽缀合物,对革兰氏阴性菌株的活性增强。
ACS Infect Dis. 2021 Sep 10;7(9):2746-2754. doi: 10.1021/acsinfecdis.1c00318. Epub 2021 Aug 13.
9
The multifaceted nature of antimicrobial peptides: current synthetic chemistry approaches and future directions.抗菌肽的多面性:当前的合成化学方法和未来方向。
Chem Soc Rev. 2021 Jul 5;50(13):7820-7880. doi: 10.1039/d0cs00729c.
10
Macrocycle-Antibiotic Hybrids: A Path to Clinical Candidates.大环内酯-抗生素杂合物:通往临床候选药物之路。
Front Chem. 2021 Apr 30;9:659845. doi: 10.3389/fchem.2021.659845. eCollection 2021.